Corrigendum to “Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents” [Bioorg. Med. Chem. Lett. 18 (2008) 6054–6057] (S0960894X08012237) (10.1016/j.bmcl.2008.10.035);Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 23, 2008, Pages 6054-6057

  Sekhar, K V G Chandra ^a   Rao, V S ^a   Vyas, D Ravi Kumar ^a   Kumar, M Murali Krishna ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT2A Antagonists; Atypical antipsychotics; Chloroethylphenylthiazoles; D2 Antagonists; Glycine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBOCROMEN; CHLOROETHYLPHENYLTHIAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; N 2 [4 (4 PIPERAZIN 1 YL) 2 OXOETHYL]ACETAMIDE DERIVATIVE; QUIPAZINE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; INFRARED SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICROANALYSIS; MICROWAVE IRRADIATION; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

MUS;

EID: 55549131866     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2017.02.064     Document Type: Erratum

References (25)

1. Lewine R.R.J., Rogg L., and Meltzer H.Y. Schizophr. Bull. 9 (1983) 368
2. Marder S.R., Wirshing W.C., and Van Putten T. Schizophr. Res. 4 (1991) 81
3. Baldessarini R.J., and Tarsy D. Annu. Rev. Neurosci. 3 (1980) 23
4. Boyd A.E., and Reichlin S. Psychoneuroendocrinology 3 (1978) 113
5. Creese I., Burt D.R., and Snyder S.H. Science 192 (1976) 481
6. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., and Summerfelt A. Am. J. Psychiatry 151 (1994) 20
7. Kane J., Honigfeld G., Singer J., and Meltzer H. Arch. Gen. Psychiatry 45 (1988) 789
8. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., and Hoschl C. CNS Drugs 20 (2006) 389
9. Buckley P.F. Biol. Psychiatry 50 (2001) 912
10. Lange J.H.M., Reinders J.H., Tolboom J.T.B.M., Glennon J.C., Coolen H.K.A.C., and Kruse C.G. J. Med. Chem. 50 (2007) 5103
11. Tamminga C.A. Can. J. Psychiatry 42 (1997) 265
12. Goff D.C., and Coyle J.T. Am. J. Psychiatry 158 (2001) 1367
13. Duncan G.E., Zorn S., and Lieberman J.A. Mol. Psychiatry 4 (1999) 418
14. Ariens E.J., Beld A.J., Rodrigues J.M.F., and Simonis A.M. In: O'Brien R.D. (Ed). The Receptors: A Comprehensive Treatise Vol. 1 (1979), Plenum, New York 33
15. Howard R.H., John A.L., Seeger T.F., Seymour A.T., Zorn S.H., Maloney P.R., Ewing F.E., Newman M.E., Schmidt A.W., Furman J.S., Robinson G.L., Jackson E., Johnson C., and Morrone J. J. Med. Chem. 39 (1996) 143
16. Leeson P.D., and Iversen L.L. J. Med. Chem. 37 (1994) 4053
17. John A.L., Seeger T.F., Nagel A.A., Howard H.R., Seymour P.A., Heym J.H., Ewing F.E., Newman M.E., Schmidt A.W., Furman J.S., Vincent L.A., Maloney P.R., Robinson G.L., Reynolds L.S., and Vinick F. J. Med. Chem. 34 (1991) 1860
18. Brain, S. F.; Antony, J. H.; Peter, W. G.; Austin, R. T. Vogels Text Book of Practical Organic Chemistry, 5th ed., 1989, p 1155.
19. 2): Calcd C, 51.88; H, 8.16; N, 22.69. Found C, 51.62; H, 8.04; N, 22.47.
20. 2S): Calcd C, 58.89; H, 6.50; N, 18.07; S, 8.27. Found C, 58.62; H, 6.26; N, 17.97; S, 7.99.
21. Costall B., Naylor R.J., and Nohria V. Eur. J. Pharmacol. 50 (1978) 39
22. Malick J.B., Doren E., and Barnett A. Pharmacol. Biochem. Behav. 6 (1977) 325
23. Costall B., and Naylor R.J. Eur. J. Pharmacol. 27 (1974) 46
24. Joshi V.V., Muley M.P., Balsara J.J., and Chandorkar A.G. Indian J. Pharmacol. 11 (1979) 293
25. Meltzer H.Y., Matsubara S., and Lee J.C.J. Pharmacol. Exp. Ther. 251 (1989) 238